Journal: Radiologie (Heidelberg, Germany)
This publication reviews recent advances in prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and PSMA radioligand therapy for advanced prostate cancer (PCa).
Key points include:
- PSMA-PET/CT shows superior accuracy in detecting PCa metastases compared to conventional CT and bone scintigraphy.
- PSMA radioligand therapy is currently used for castration-resistant PCa patients with adequate PSMA expression and disease progression after chemotherapy and androgen receptor pathway inhibitors.
- Ongoing and future studies aim to evaluate the efficacy of PSMA radioligand therapy in earlier disease stages and in combination with other treatments.